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Abstract
Lower back pain (LBP) occurs in 80% of adults in their lifetime; resulting in LBP being
one of the biggest causes of disability worldwide. Chronic LBP has been linked to the
degeneration of the intervertebral disc (IVD). The current treatments for chronic back
pain only provide alleviation of symptoms through pain relief, tissue removal, or spi-
nal fusion; none of which target regenerating the degenerate IVD. As nucleus
pulposus (NP) degeneration is thought to represent a key initiation site of IVD degen-
eration, cell therapy that specifically targets the restoration of the NP has been
reviewed here. A literature search to quantitatively assess all cell types used in NP
regeneration was undertaken. With key cell sources: NP cells; annulus fibrosus cells;
notochordal cells; chondrocytes; bone marrow mesenchymal stromal cells; adipose-
derived stromal cells; and induced pluripotent stem cells extensively analyzed for
their regenerative potential of the NP. This review highlights: accessibility; expansion
capability in vitro; cell survival in an IVD environment; regenerative potential; and
safety for these key potential cell sources. In conclusion, while several potential cell
sources have been proposed, iPSC may provide the most promising regenerative
potential.
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1 | INTRODUCTION
1.1 | Lower back pain and treatment
Lower back pain (LBP) is the biggest cause of disability worldwide,
around 80% of adults will suffer from LBP in their lifetime.1,2 Most
people experience mild pain and recover quickly; however, it is com-
mon for episodes of LBP to relapse contributing to a lifelong disability
and a large societal burden.1,3 The current mainstay of treatments to
combat LBP are split into pharmacological (opioids, non-steroidal anti-
inflammatory drugs, antidepressants) and non-pharmacological (physi-
cal therapy, exercise, massage and manipulation, and alternative
therapies (acupuncture, magnet therapy, and reiki).4-8 Although these
treatments are potentially helpful in acute LBP, there are limited ther-
apies that are efficient in the management of chronic LBP.9-12 For
example, treatments available to relieve chronic LBP and recurrent
onset back pain include an invasive operation to remove the IVD and
potentially fuse adjacent vertebrae, which can lead to the alteration of
the normal physiological and biomechanical function of the spine.13 In
some cases spinal fusion can increase the risk of adjacent segment
disease, where the spinal segment directly below or above the site of
the fused IVD experiences increased biomechanical demands, which
can lead to accelerated IVD degeneration.14,15 The use of painkillers
for the treatment of chronic LBP has also had repercussions, with
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24% of chronic LBP cases reported to result in aberrant medication-
taking behaviors.16 Such behaviors are contributing to the opioid epi-
demic in the United States17 and the development of an opioid crisis
in the United Kingdom and other countries.18 In the United States
there were 70 237 opioid overdose deaths in 2017, which constituted
67.8% of overall drug related overdoses.19 Therefore, there has been
an emphasis to reassess the management of chronic LBP.20 Approxi-
mately 40% of all chronic LBP cases are associated with IVD degener-
ation.21-23 However, none of the treatments stated above address the
underlying cause of IVD degeneration and target the restoration of
the damaged IVD.24
1.2 | Intervertebral disc, degeneration, and
discogenic back pain
The IVD is a complex structure, where the biomechanical functioning
of the IVD relies on a balance between the three main tissues that
compose it. The central aspect of the IVD contains a glycosaminogly-
can-rich gel-like tissue called the nucleus pulposus (NP), which is
enclosed by the annulus fibrosus (AF). The third distinct region are the
cartilaginous endplates (CEP), which are composed of cartilage and
situated superiorly and inferiorly to the IVD, and act to separate and
anchor the IVD to the vertebrae via the bony end plates, the CEP also
act as a gateway for nutrient transport into the IVD.25,26 The different
compositions of the three areas of the IVD allow the support of spinal
compressive loads, the NP osmotically exerts the swelling pressure
while the AF constrains the NP, preventing it from protruding trans-
versely and the CEP constrains the NP from bulging into the adjacent
vertebrae; thus creating tensile stresses and absorbing the consider-
able hydrostatic pressure.26,27 A healthy IVD requires maintenance of
this homeostatic environment, a simple shift in the matrix properties,
cells, or molecular signals in these three areas of the IVD has implica-
tions to the distribution of the mechanical load and begins the cas-
cade of IVD degeneration. The disruption of this homeostatic balance
is multifactorial, and may start at the cellular level caused by, for
example, nutrient deprivation due to ossification of the endplates, or
could initiate via a structural defect that can cause subsequent cellular
changes.28
The regulation of cellular turnover is vital to tissue homeostasis.
In IVD degeneration the number of functional cells are decreased,
through apoptosis and cellular senescence,29-32 with an accompanied
phenotypic shift toward catabolism; which leads to altered NP matrix
maintenance and an increase in catabolic responses by the IVD cells
themselves.33-36 NP matrix composition is regulated through cellular
matrix synthesis and matrix degradation via the activity of matrix
metalloproteinases (MMPs) and A disintegrin and metalloproteinase
with thrombospondin motifs (ADAMTS), enzyme families, which can
be inhibited by tissue inhibitors of metalloproteinases (TIMPS).36
Healthy NP tissue contains a ratio of 27:1 glycosaminoglycan-to-
hydroxyproline (collagen) ratio, and aggrecan and its associated gly-
cosaminoglycans (GAGs) preserves the high water content of the
NP.37 During degeneration, NP matrix synthesis and degradation
becomes dysregulated leading to the loss of proteoglycans and dehy-
dration. The condensed NP and increase in intradiscal pressure results
in reduced capacity of mechanical loading of the IVD leading to the
creation of microfissures throughout the IVD.38 Once the outer AF is
ruptured or the CEP has fractured, inflammatory cells can migrate into
the IVD which propagates an inflammatory cascade. This together
with the catabolic factors produced by the native IVD cells, contrib-
utes to discomfort and the stimulation of pain sourced from the IVD,
also known as discogenic pain.38,39 There is no definitive mechanism
to explain the link between IVD and the discogenic pain patients
experience. However, the combination of structure disruption with
the production of angiogenic and neurotrophic factors by NP and AF
cells, stimulates angiogenesis and promotes neural ingrowth to the
largely avascular and aneural IVD.39,40 The IVD cells also produce pain
sensitizing factors such as substance P, which can sensitize in-growing
nerves and local nerve roots to pain.40,41 Thus, it is important to
deduce a regenerative approach that will restore the balance of cells,
extracellular matrix and the biomechanics of the IVD and interrupt the
viscous cycle of degeneration.42,43
1.3 | Potential approaches to regenerate the
nucleus pulposus
There has been a focus for a tissue engineering approach to restore
the appropriate cell and matrix content of the NP, which would bene-
fit the function of the IVD as a whole and thus resolve discogenic
back pain.43-45 These studies have ranged from biomaterial-based to
cellular approaches or a combination thereof. Some studies have
investigated implanting biomaterials to stimulate the resident NP
cells,46-48 while others have used biomaterials to act as a combination
of mechanical support and as a cell carrier system.49-51 Cell therapy
has been proposed to restore the NP cell population, as the loss of
viable cells and a shift to a catabolic phenotype is one of the charac-
teristics of IVD pathogenesis.52-54
An important consideration in the choice of cell source for thera-
peutic use is the origin of cells of the IVD. Developmentally, the IVD's
unique structure is formed from cells of at least two embryonic ori-
gins: the notochord, which develops into the NP and the sclerotome
which makes up all other connective tissue of the spine including the
AF and vertebrae.44,55 The notochord and sclerotome are derived
from one of the three primary embryonic germ layers: the mesoderm
(Figure 1A).56,57 Therefore, a cell-based therapy approach could be
performed using cells that have the capacity to develop into, and
from, the mesoderm-derived lineages (Figure 1B). Such as differenti-
ated cells: notochordal (NC) cells,58 NP cells,59,60 AF cells,61 and cho-
ndrocytes62,63; adult stromal cells from bone marrow or adipose64-66;
embryonic stem cells,67,68 or more recently the use of induced plurip-
otent stem cells (iPSC) have also been explored.69-71 However, this
straightforward cell therapy strategy is made much more difficult by
the fact that the microenvironment of the IVD is very harsh. The IVD
environment has an acidic pH, due to high concentrations of lactate,29
low concentrations of glucose and oxygen,72 and fluctuating
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osmolarity73-75; the degenerate IVD also contains increased expres-
sion of catabolic cytokines,36,76 that further disrupt this harsh envi-
ronment. Therefore, the cells will also need to be able to adapt and
survive in the IVD niche.
There have been a wide range of potential cell sources explored
for the repair and regeneration of the IVD which will be explored
within this systematic literature review. Specifically, this systematic lit-
erature review will discuss the cell sources investigated for the regen-
eration of the NP, from terminally differentiated cell sources, to the
use of adult stem cells and recent studies investigating iPSC.
2 | METHODS
PubMed was used as the principal database with a primary search of
“([disc degeneration] OR [intervertebral] NOT [retinal]) AND ([embry-
onic stem cells] OR [progenitor cells] OR [fibroblasts] OR [stem cells]
OR [induced pluripotent stem cells] OR [adult stem cells] OR [mesen-
chymal] OR [adipose] OR [hematopoietic] OR [synovial] OR [disc stem
cells] OR [disc cells] OR [nucleus pulposus] OR [chondrocytes] OR
[notochordal] OR [notochord]) AND ([cell therapy] OR [regeneration]
OR [therapy] OR [treatment]).” Clinical trials, in vivo and in vitro stud-
ies were all included, and the search was limited to the English lan-
guage and published prior to 31 December 2020. These keywords
were chosen to explore the different types of cell sources to be used
as potential regenerative therapies for the IVD. This search generated
a total of 3566 publications. The title and abstracts were initially
screened based on their relevance to cellular therapies for the regen-
eration of the NP region only. A total of 355 articles were identified.
In order to review the regenerative potential of each cell, the
studies identified from the literature search was used systematically
to first identify their native phenotype. Followed by the ability of the
cell type to be handled in an in vitro setting, such as, cell expansion
capability, and maintenance of phenotype. Next, the survival of the
cell type within the IVD environment was evaluated. Finally, regenera-
tive effects, if any, of the selected cell type was reported predomi-
nately in vivo systems. From these analyses each cell source was
ranked based on the cells accessibility, expansion capability in vitro,
survival in IVD, ECM production, and potential adverse effects on a
scale of 0 to 3. Using the sum of each feature, the cell source was
F IGURE 1 Cell sources and linages involved in cellular therapy in regenerating the intervertebral disc. (A) Schematic illustration depicting key
stages of intervertebral disc development, highlighting the mesodermal origin of the notochord and sclerotome that evolve into the nucleus
pulposus, annulus fibrosus and vertebral bodies. Red arrows show the potential cell sources. (B) An illustration of the mesenchymal stem cell and
notochordal cell differentiation lineages (black arrows). Under appropriate culture conditions transdifferentiation can be induced to develop
different cell types (black dash arrows), which can interlink different cell lines
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given an overall rating on a scale of 0 to 15 to enable a semiquantita-
tive comparison of potential for IVD regeneration.
3 | TRENDS IN CELLULAR THERAPY
RESEARCH FOR INTERVERTEBRAL DISC
REGENERATION
There has been a gradual increase in the number of studies investigating
potential cellular therapy to regenerate the NP, with the first studies
reported in 1994. Over the last 16 years, a 50% increase has been seen
(Figure 2). Initial studies focused on the use of NP cells, either alone or
augmented with growth factor stimulation or anti-catabolic therapies
(Figure 3). From 2003 onwards, initial studies were reported investigat-
ing the use of adult stem cells and alternative terminally differentiated
cells (Figure 3C). From then on bone marrow stem cells (BMSC) have
been the predominant cell choice, with 40% of the literature reporting
studies using BMSC, followed by NP cells and then ADSC (Figure 3B).
From 2013 onwards, cells that have pluripotent and multipotent capa-
bility were first reported, with the use of human umbilical cord stem
cells (hUCSC) and iPSC (Figure 3). Most of the studies have utilized
in vitro cell culture (42%) and in vivo small and large animal models
(39%) (Figure 4A,B), as organ and tissue culture models were only intro-
duced in 2008 (Figure 4C). One of the earliest in vivo studies was con-
ducted in a dog IVD degeneration model in 1994, after that smaller
animal models were favored; in 2009, studies progressed to a higher
incidence of large animal models, with the first clinical human trial being
implemented in 2006, 12 years after the first study on cell therapy. The
first human clinical trial was reported using hematopoietic stem cells77;
9-fold more clinical trials have been conducted on humans than in dogs
(Figure 4C). Greater than 50% of the in vivo studies utilized small animal
models, with rabbit being the dominant species (Figure 5B); due to the
ease of accessibility and cost implications.78 Less than half of studies
utilized large animal models, with dog being the most utilized large
animal model and no studies used cow models (Figure 5A). Similarities
between human and animal IVD have been previously reviewed by Alini
et al. (2008) and will not be part of the discussion of this review. How-
ever, it is worth noting that a significant limitation when analyzing ani-
mal models for regenerative approaches is that many of the species
utilized retain their immature NCs and thus have an increased regenera-
tive capability which can skew results. Thus, model systems which lose
NCs postnatally, such as sheep, goats and chondrodystrophic dogs,
would be more appropriate for investigations into regenerative
approaches.79
4 | PROPOSED CELL SOURCES FOR
NUCLEUS PULPOSUS REGENERATION
This review discusses the key cell types investigated for regenerative
approaches and discusses their potential applicability for lower back
pain. With a focus on native phenotype, accessibility, survival, expan-
sion capability, and tolerance of the IVD environment. Leading to rec-
ommendations for potential cell sources for tissue regeneration
approaches and their limitations. Cell types will be discussed in order
of terminal differentiation, namely differentiated cells (NP, AF, NC,
and chondrocytes); followed by adult stromal cells (BMSC, ADMSC,
and UCSC); and finally, iPSC. Other cell types were not further ana-
lyzed as only a limited number of studies utilized them. These
included: fibroblast cells,80-83 gynecological cells (menstrual blood
derived stem cells and human amniotic cells),84,85 hematopoietic stem
cells,77 hESC,86-88 muscle derived stem cells,89 olfactory stem cells,90
and synovial derived mesenchymal stem cells.91,92 Cellular therapies
have been proposed either as cells alone or together with instructive
biomaterials or growth factors to support regenerative properties.
This review aims to focus on the choice of cell source for regenerative
approaches and thus will not discuss the combinations with biomate-
rial and growth factors which have been reviewed elsewhere.68,93-96
F IGURE 2 Publication
intensity for cellular therapy for
NP regeneration. The number of
studies investigating potential
cellular therapy to regenerate the
NP extracted from the literature
review search expanding over
26 years (from January 1994 to
December 2020)
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5 | NUCLEUS PULPOSUS CELLS
5.1 | Native phenotype
NP cells within the mature human IVD are rounded and situated
within a lacunae,* the NP cell produces abundant proteoglycans
and collagen type II, with phenotypic makers of Forkhead Box
F1 (FOXF1), paired box 1 (PAX1), Keratin 19 (KRT19) among
others.44,91-100 NP tissue also contains a population of NP pro-
genitor cells98,101-103 which have been suggested to be NP-
derived stem cells although their full characterization as stem
cells has not been completed. NP progenitors in vitro are pres-
ented as elongated spindle shape cells,104 which are positive for
Tie2 and express stem cell genes (eg, Sox2, Oct3/4, Nanog,
CD133, Nestin, and neural cell adhesion molecule).8,103,105 These
NP progenitors were positive for CD73, CD90, and CD105.70 NP
cells show potential for osteogenic, adipogenic and, in
F IGURE 3 Cell sources proposed for NP regeneration: Studies investigating potential cellular therapy to regenerate the NP expanding over
26 years (from January 1994 to December 2020) were classified according to cell source proposed: the number (A), percentage (B) of cell type and the
percentage of cell type relative to the year (C) which used the following cell types: Adipose derived mesenchymal stem cells (ADMSC), annulus fibrosus
(AF) cells, bone marrow derived mesenchymal stem cells (BMSC), chondrocytes (subgroups include: endplate chondrocytes, hyaline chondrocytes,
articular chondrocytes, nasal chondrocytes, and auricular chondrocytes), fibroblast cells, gynecological cells (subgroups include: menstrual blood derived
stem cells, and human amniotic cells), hematopoietic stem cells, human embryonic stem cells (hESC), human umbilical cord stem cells (hUSC; including
placenta derived mesenchymal stem cells), induced pluripotent stem cells (iPSC), muscle derived stem cells, notochordal cells (NC), nucleus pulposus
cells (NPC), olfactory stem cells, and synovial derived mesenchymal stem cells. (B) From the literature extracted: 40% used BMSC; 26% used NPC; 12%
ADMSC; 6% used chondrocytes; 3% used iPSC; 3% used hUSC; 3% used NC cells; 2% used AF cells; 2% used fibroblasts; <1% used hESC; <1% used
synovial MSC; <1% used gynecological cells; <1% used olfactory SC; <1% used muscle SC; <1% hematopoietic SC
*Conclusion; Table 1. Accessibility of NP cells is ranked 1, as these cells are situated in the NP
within the IVD. Therefore, difficult to access and unable to use autologously.
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comparison to AF and CEP cells, maintain the greatest
chondrogenic potential.106,107
5.2 | Expansion capability and maintenance of
phenotype
Human NP (hNP) cells are versatile, they can be harvested from cadavers,
surgical samples99 and can be cryopreserved without altering cell integ-
rity.108 However, the numbers of cells retrieved are relatively low and
in vitro expansion would be required to yield enough cells for further ther-
apy. Furthermore, hNP cells extracted from degenerative IVDs undergo
cellular senescence at an accelerated rate; and express a decreased replica-
tive potential when compared with IVD cells extracted from non-
degenerate IVDs.30† Rapid de-differentiation and phenotypic alterations
of NP cells happen within the first passage of monolayer expansion or
serial passaging in NP.107,109 Whereas continuous expansion110 and other
three-dimensional (3D) culture systems such as NP pellet,111 algi-
nates33,109 or spheroid culture system103 leads to the maintenance and
restores NP phenotype. Co-culture of hNP cells with other cell types can
result in a positive effect on cell viability and proliferation, for example,
doubling proliferation was seen when co-cultured with autologous hBMSC
for 3 days.112 Unfortunately, many studies utilizing hNP cells for regenera-
tive studies do not report the passage number where cells were utilized,
however the majority of studies that state this, limit passage number to a
F IGURE 4 Study type utilized to investigate cellular regeneration of the NP. Studies investigating potential cellular therapy to regenerate the
NP expanding over 26 years (from January 1994 to December 2020) were classified according to the type of study performed; the number (A),
percentage (B) of study type and the percentage of study type relative to the year (C) from the literature search that used the following model
systems: in vitro (including 2D and 3D culture), tissue explants, organ culture, in vivo (subcutaneous or injected into a healthy or degenerate
intervertebral disc), canine clinical trials and human clinical trials
†Conclusion; Table 1. Expansion capability of NP cells is ranked 2, as these cells have low cell
number from harvesting and inability to expand in monolayer culture conditions.
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maximum of three passages62,98,110,112-118 and thus limit induction of cel-
lular senescence and retain re-differentiation capacity.33,119,120
5.3 | Cell survival in the intervertebral disc
environment
Naturally, NP cells are adapted to survive within the harsh environment of
the IVD,121,122‡ however when these cells are removed from the IVD and
cultured within monolayer in non-physiological conditions they may lose
their adaptations to this environment. In vitro culture is often utilized
when testing cells in IVD conditions such as pH, osmolarity, and oxygen
concentrations are easier to manipulate.123-125 In altered pH conditions
that resemble mild to severe degenerative IVD, NP cell viability and prolif-
eration was sustained in low pH124; rabbit NP (rbNP) cells cultured in
pH 7.4 displayed an increase in apoptosis and decrease in cell proliferation
compared with pH 6.5, indicating that NP cells prefer mild acidic condi-
tions. When directly comparing rat NP (rtNP) cells to rtADMSC, it has
been demonstrated that NP cells were less sensitive to acidic conditions
and produced lower catabolic metabolism.124 It has previously been
reported that matrix metabolic activity is also enhanced when cultured
under acidic pH in bovine NP (bNP) cells.126 This is an indication that bNP
favors physiological conditions in comparison to hNP; high glucose also
F IGURE 5 Animal model utilized for investigation of cell therapies for NP regeneration. In vivo studies (including human clinical trials, canine
clinical trials, and in vivo study types) investigating potential cellular therapy to regenerate the NP expanding over 26 years (from January 1994 to
December 2020) were classified according to the animal model utilized; the number (A), percentage of animal model used (B) and the percentage of
animal model used relative to the year (C) from the literature search that used the following living animal model system: human, monkey, dog, cow, pig,
sheep, goat, rabbit, rat, and mouse
‡Conclusion; Table 1. Survival capability of NP cells in IVD environment is ranked 3, as these
cells are derived from the IVD and are adapted to survive in that physiological environment.
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increased extracellular matrix gene expression in bNP cells comparedwith
hNP cells.127 A report of rtNP progenitors cultured in IVD-like high osmo-
larity using NaCl (400 mOsm/L) showed increased proliferation than iso-
lated rtNP cells, whether under standard (280 mOsm) or high osmolarity
conditions (400 mOsm/L).123 However, hNP cells cultured in high osmo-
larity increased proteoglycan production.128 Low oxygen was not detri-
mental to matrix synthesis for bNP and even promotes the ideal NP
phenotype, through an increase in aggrecan, and collagen type 2
markers.129 At low oxygen concentration hypoxia-inducible factor-1
(HIF-1α) was mostly localized to NP cells, more so than other cells.130,131
HIF-1α is a crucial physiological regulator in anaerobicmetabolism and the
constitutive expression of HIF-1α by a NP cell indicates their ability to
survive and adapt to hypoxic conditionswithin the IVD.132
IVD conditions of altered pH, osmolarity and oxygen have a
strong influence on metabolic rates, matrix production and cell sur-
vival.133 In monolayer, NP and NP progenitor cells have the ability to
adapt and survive in IVD culture conditions, favoring altered pH,
osmolarity, and oxygen to IVD physiological standards, which results
in proteoglycan production. Given these findings NP cells seeded into
a IVD organ, have the potential to survive, proliferate and produce
regenerative extracellular matrix. However, the culture of isolated
cells prevents all cell-matrix interactions and signaling and thus, NP
cells could act differently when cultured in in vivo systems.133
NP cells transplantation into in vivo models have also been investi-
gated and studies have shown that the transplanted NP cell remain viable
for a number of weeks and months; allogeneic expanded rtNP cells
remained viable for 4 weeks in a rat model134; in a canine model,
cryopreserved autologous cNP cells were observed at 12 weeks115 and
12 months of allogeneic expanded cNP cells62; xenogeneic transplanta-
tion of a hNP established cell line were sustained in a rabbit model for 8
and 24 weeks,98,135 12 weeks in a monkey model100 and 12 weeks in a
caninemodel.116 Interestingly, transplanted NP cells weremainly localized
in the injected zone, with observation of cells migrating into the inner AF
in canine and rat treated models. Suggesting that injected NP cells have
the ability to migrate and integrate with native cells.115,136 Once migrated
to the inner AF, the cell takes upon themorphology of the native cell, such
as an AF spindle-like shape. Whereas, the rtNP cells which stayed within
the NP maintained their rounded shape.134 Establishing that NP cells can
remain viable and proliferate inmost conditions and differing animal host.
5.4 | Regenerative effect of nucleus pulposus cells
hNP cells produced aggrecan and type II collagen and low levels of type I
collagens, for up to 24 weeks when compared with the degenerate con-
trol in a number of in vivo systems.62,98,118§ However, it has been
observed that regenerative effects may differ depending upon the cell
sources administered. Rosenzweig et al. (2017) observed a difference
proteoglycan expression of bNP and hNP cells; bNP cells resulted in
higher expression of collagen type II and aggrecan.110 Whereas, in
expanded hNP cells protein expression was not preserved and less colla-
gen type II and aggrecan were observed.110 These differences may have
been due to the source of hNP cells, which were from herniated degen-
erate IVDs,110 which have been shown to have higher levels of cellular
senescence and increased inflammatory factors than non-degenerate
discs.30 There are reports that herniated cells have limited regenerative
potential as they show signs of de-differentiation, degeneration, and
decreased aggrecan and collagen type II production.30,114¶
hNP cells implanted into in vivo models, displayed partial regenera-
tion of IVD height,116 specifically, the results showed initial IVD
narrowing due to degeneration prior to implantation, followed by
regenerated IVD height of 14.8%, after 3 weeks analyzed usingmagnetic
resonance imaging (MRI),115 18.91% and 9.7% after 4 weeks using X-
ray,135,137 and 7% to 15% after 8 weeks using X-ray,118 in comparison to
the degenerate control. Chen et al. (2016) reported that hNP and hNPSC
injected into rabbit degenerate induced IVDs, and after 12 weeks there
appeared to be no significant difference in the degenerate IVD control
and was actually significantly lower than in the normal “healthy” IVD.98
An MRI analysis using relative signal intensity index suggested that the
NPSC group restored IVDheight greater than theNP cell and degenerate
control, however, in most studies the IVD height was still less than that
of a healthy IVD.98,115,116,118,135 Despite improvement to IVD height
seen in most studies and GAG production, NP cells used to regenerate
the IVD were able to halt further degeneration, but not significantly
improve the degenerate condition in the context of Pfirrmann classifica-
tion; which was reported at Grade 2 to 3,112,115 whereas the degenerate
IVDs displays progressive degeneration toGrade 3 to 5.115
5.5 | Concluding remarks
NP cells are able to demonstrate long term survival in vivo and display
their ability to adapt to the IVD microenvironment, including differ-
ences to osmolarity, oxygen, and pH conditions, however NP progeni-
tor cells also have this ability and further displayed regenerative
effectiveness. Recently, NP progenitor cells have been successfully
expanded from NP cell populations following spheroid culture sys-
tem.103 It was reported that animal NP cells differed in responsiveness
and bNP cells were less representative of hNP cells. NP cells demon-
strated their ability to produce GAG for regenerating a degenerate
IVD, with slight restoration. However, the main issue with the use of
native NP cells in a regenerative approach is the sourcing of these
cells as harvesting from a normal IVD would induce IVD degeneration,
but if cells are harvested from an already degenerate or herniated
IVD, these cells would show increased catabolism and thus reduced
regenerative capacity, although sourcing from cadavers could be a
possibility. NP progenitor cells are currently in clinical trials
(DiscGenics),118 while NP cell-based clinical trials138 have been com-
pleted and the results of these studies will be interesting to follow.
§Conclusion; Table 1. NP cell's ability to produce extracellular matrix is ranked 3, as these cells
produce aggrecan and collagen type II, which are extracellular matrix physiologically found in
the NP region of the disc.
¶Conclusion; Table 1. The potential adverse effects of using NP cells is ranked 2, as NP cells used
from a degenerative disc sources resulted in less regeneration of disc and an increase in
catabolic enzymes and inflammatory factors. Subjecting patients through treatments that
may result in no significant improvement.
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6 | ANNULUS FIBROSUS CELLS
6.1 | Native phenotype
AF cells in the inner AF are rounded, chondrocyte-like cells. Progressing
to the outer AF, cells are more elongated in morphology, similar to fibro-
blasts.139 The outer AF is mechanically strong matrix composed of a
higher ratio of collagen type I to type II, resulting from expression of
COL5A1, a gene that regulates collagen type I assembly.59,140,141
6.2 | Expansion capability and maintenance of
phenotype
The expansion capability for AF cells is very similar in some ways to NP
cells. The same method of cell isolation** and expansion is often
used107,142 which extracts, per grams of tissue, roughly the same low
density yield of cells as NP.143,144†† AF cells also share a similar pheno-
type: positive for CD44, CD73, CD90, CD105, CD151, and CD166 and
negative for CD34, CD45, CD146, and similar transcriptome profiling to
NP cells.145 However, van den Akker et al. (2020) published a set of
novel membrane-associate markers for NP and AF cells, thus dis-
tinguishing the few markers specific for AF, for example, secreted friz-
zled related protein 2 (SFRP2) and COL1A1.146 Similar to NP cells, AF
cells show osteogenic and chondrogenic potential, but with a greater
number of highly expressed stemness genes.107 This review focuses on
the cell sources for NP regeneration, and while AF cells have been more
commonly studied as potential regenerative strategies for AF tissues and
have been reviewed elsewhere,147-149 some studies have also investi-
gated their use for NP regeneration which will be explored further here.
6.3 | Cell survival in the intervertebral disc
environment
As AF cell are native to the IVD environment, it is no surprise that
when transplanted into in vivo rabbit IVDs, >90% of allogeneic AF
cells were viable 12 weeks post-transplantation.141‡‡
6.3.1 | Regenerative effect of annulus fibrosus cells
The majority of studies utilizing AF cells in this literature search were
in vitro methods, with two papers studying AF cells in rabbit IVD degen-
eration models.141,150 AF cells in vitro have been shown to produce elas-
tin24,141,151 and predominantly collagen type I, where collagen type II
remained undetected.49,142,152 Even in different biomaterial culture
conditions, AF cells seen to favor the synthesis of collagen type I, a char-
acteristic of native fibrocartilaginous AF tissue.49,142,152§§ The two in
vivo studies highlighted that collagen type II and aggrecan were
upregulated.153 The structure of the inner AF was significantly
preserved,153 suggesting the AF cells are drawn toward the AF region
rather than staying in the NP and strong safranin-O staining was
observed in the AF cell-transplanted NP tissue, which is very histologi-
cally similar to hyaline-like cartilage and normal AF.141
6.4 | Concluding remarks
The use of AF cells for NP tissue regeneration would not be a preferred
cell choice due to the fact that they predominately produce an
unflavored collagen type I and cartilage-type matrix, which did not
resemble the native extracellular matrix of the NP.¶¶ Thus, in the
IVD regeneration field, AF cells in are mainly utilized for AF
repair.151,152,154-156 However, where AF cells are targeted for AF repair,
the use of cell therapies for such an approach would need to also con-
sider the risk of implanted cells leaking from the disc following AF dam-
age and rupture. There are a couple of reviews that have discussed large
animal and clinical trials studies that target the “sealing” of AF to prevent
NP herniation which is outside the scope of the current review.144,157
7 | NOTOCHORDAL CELLS
7.1 | Native phenotype
Notochordal (NC) cells are distinct through their relatively large size
(>20 μm) and presence of vacuoles.158,159*** In many studies this clas-
sic physaliphorous phenotype was used to distinguish between other
NP cell types.160
7.2 | Expansion capability and maintenance of
phenotype
In standard monolayer culture, the NC vacuoles cells were lost with
expansion of porcine NC (pNC) cells after 28 days161,162 or within 1
to 3 passages160; canine NC (cNC) cells observed a loss in NC char-
acterization after 6 days in monolayer culture.163 It was reported
that NC cells acquired a NP-like morphology (small, round cells) and
became indistinguishable from NP cells.160,161 There are additional
reports of a decrease in NC cell marker expression such as
Brachyury,160 Keratin (KRT) 8, and KRT19.161 Gantenbein et al.
(2014) reported that when pNC cells are cultured in monolayer,
**Conclusion; Table 1. Accessibility of AF cells is ranked 1, as these cells are situated in the AF
within the IVD. Therefore, difficult to access and unable to use autologously.
††Conclusion; Table 1. Expansion capability of AF cells is ranked 2, as these cells have low cell
number from harvesting.
‡‡Conclusion; Table 1. Survival capability of AF cells in IVD environment is ranked 3, as these
cells are derived from the IVD and are adapted to survive in that physiological environment.
§§Conclusion; Table 1. AF cells ability to produce extracellular matrix is ranked 2, as these cells
produce cartilage like matrix, which is not phenotypic of the NP region.
¶¶Conclusion; Table 1. The potential adverse effects of using AF cells is ranked 2, as using this
cell source would not result in a regeneration of the native matrix production, thus subjecting
patients through treatments that results in no significant improvement.
***Conclusion; Table 1. Accessibility of NC cells is ranked 0, as these cells are only situated in
the NP region of certain species of animals and in humans under the age of 10.
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they are outcompeted by smaller (<8 μm) NP cells, despite the cul-
ture starting as 80% NC cell population. Kim et al. (2009)
highlighted that NC cells grown in monolayer culture had a signifi-
cantly slower growth rate of 135 hours population doubling time
compared with NP cells which showed a growth rate of 23 hours
population doubling time. This is in conjunction with the observa-
tion that single isolated NC cells morphologically differentiated into
three distinct cell types: NC vacuolated cells, giant cells, and small
NP cells.74,158 As a result, alternative methods such as co-culturing
NC with other cells and culturing in 3D in vitro culture models have
been investigated. When cNC cells are co-cultured with cMSC, an
increase in proteoglycan production and maintenance of NC pheno-
type was observed.164 pNC cells were shown to have high cell via-
bility for up to 42 days in alginate bead culture,165,166 with one
study reporting up to 80% cell viability at 10 days in rbNC.158
Gantenbein et al. (2014) reported that a higher fraction of around
50% of pNC cells were recoverable after 34 days of culture when
compared with the identical cell population grown in monolayer.
Providing evidence that keeping NC cells in 3D cultures, which
would resemble their in vivo cluster form, rather than completely
isolating them in monolayer, could preserve the NC cell phenotype
better during in vitro culture.74,160,167†††
7.3 | Cell survival in intervertebral disc
environment
NC cells are sensitive to culture conditions. Osmolarity has been
shown to affect NC cell phenotype, Spillekom et al. (2014) demon-
strated cNCs cultured in αMEM at 400 mOsm/L contained more
vacuolated cells and showed significantly higher brachyury expres-
sion compared with high glucose DMEM/F12 and αMEM both at
300 mOsm/L. Guehring et al. (2009) established that NC cells are
also highly metabolically active; consuming more oxygen and glucose
and producing more lactate compared with NP cells. Thus, NC cells
exhibit a strong nutrient dependency,160,166 which resulted in some
studies altering the culture condition when culturing NC cells: such
as adding 10% fetal calf serum supplement.160 In addition, co-cultur-
ing NC with other cells (eg, NP cells) at a lower ratio of 30:70166
reduces nutrient depletion, preventing NC cell death.166 Further, NC
cells were more sensitive to nutrient deprivation than other IVD cells
and were found to not survive under conditions which NP cells were
still viable. Interestingly, the porosity of the cartilage endplate is corre-
lated with the nutrient supply and presence of NC cells.168-171 Despite
NC cell sensitivity in nutrient deprivation, culture preference is with low
glucose media αMEM at 400 mOsm/L.74 Finally, oxygen content as
Gantenbein et al. (2014) observed, also plays a role in NC cell marker
expression. Brachyury and CD24 was only expressed in the 2% oxygen
conditions and downregulated in the 20% oxygen, indicating that NC
cells were functional only in physioxia conditions.107,160 Despite these
findings, to date ideal culture conditions have not been established for
NC cells.
IVDs are subject to other stimuli which could impede NC cell's
ability to regenerate the IVD, such as mechanical loading exerted
in vivo and its effect on the NC cell metabolism and biosynthesis. Pur-
messur et al. (2013) used an ex vivo model of pNC cell-rich NP tissue
loaded into a hydrostatic pressure chamber and subjected the tissue
to a daily load of 0.5 to 2 MPa at 0.1 Hz for 2 hours.165 Despite the
reported increase in proteoglycan accumulation observed in the daily
loading control, the histological images show the cell population tran-
sitions from ~75% of large NC cells being observed in the control to
~25% in the daily pressurization control. Which together with the lack
of evidence of apoptosis, supports potential differentiation into small
NP cells under load. The study concluded that NC cells were able to
withstand the hydrostatic loading, with the daily loading regime caus-
ing little effect on cell viability in comparison to the controls. None-
theless, the results showed that the large vacuolated morphology of
NC cells decreased under load, suggesting alteration in cell
phenotype.‡‡‡
7.4 | Regenerative effect of notochordal cells
Due to the loss of NC cell phenotype in culture, efforts have been
made to improve regenerative effects by co-culturing NP cells with
other cells or 3D culture. Most studies investigated NC cells with a
co-culture of NP cells. A significant increase in the GAG/DNA ratio at
7 days, irrelevant of oxygen concentration was observed with the co-
culture of pNC cells and bNP,160 which after 14 days GAG/DNA ratio
was only significantly increased in specifically the 2% oxygen culture
conditions. However, other studies observed only slight increase in
GAG or insignificant change in extracellular matrix content when cNC
and cNP were co-cultured164; and pNC and bNP cells were
co-cultured.162,166 In respect of specific extracellular gene expression:
Arkesteijn et al. (2017) demonstrated the inhibitory potential of NC
cells on collagen type I expression, as an increased expression in colla-
gen type I was significantly increased in the degenerative control and
not in the pNC cells control.166 Aggrecan was upregulated in the co-
culture pNC cells and bNP at 14 days160 and cNC cells cultured in
αMEM 400 mOsm/L conditions at 28 days.74 In Arkesteijn et al.
(2017) and Potier and Ito (2014) there was no significant increase in
collagen type II reported in in vitro NC controls, however both studies
also documented the loss of NC cell morphology,161,166 whereas Spi-
llekom et al. (2014) observed collagen type II in cNC cultured at
28 days in higher osmolarity and lower glucose conditions.74 A major
limitation with the co-culture of NC and NP cells, is that, as previously
discovered, both cells proliferate at different rates and thus NCs could
be overcrowded by the proliferation of NP cells,74,162 and NC
demanding dependency of culture conditions. NC cells show constant
DNA content throughout culture and are able to display an increase in
†††Conclusion; Table 1. Expansion capability of NC cells is ranked 1, as there's limited
experience in handling these cells in research and the few research has shown that NC cells
are problematic in monolayer and in continuous expansion culture conditions.
‡‡‡Conclusion; Table 1. Survival capability of NC cells in IVD environment is ranked 2, as these
cells are derived from the IVD and are adapted to survive in that physiological environment,
although they show increased nutrient demand and do not appear in mature human IVDs.
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proteoglycan production through a high GAG/DNA ratio, thus demon-
strating an efficient phenotype for producing extracellular matrix
within the limited nutrient environment of the IVD. Furthermore,
Cappello et al. (2006) reported cNC cells were capable of producing
proteoglycans at a 1.5-fold greater rate of synthesis than cNP cells;
thus, indicating that the extracellular matrix produced by NC cells is
assembled in a distinct manner different to NP cells, as proteoglycans
secreted from NC cells migrate and aggregate quicker compared with
NP cell synthesized proteoglycans§§§.172 The next question would be:
is the extracellular matrix produced by NC cells more favorable to reg-
enerating the degenerative IVD in vivo?
There have been limited use of NC cells in vivo models, however
the studies that have used NC cells for regeneration of degenerative
IVDs have shown promising results. Liu et al. (2018) used rtNC cells in
a rat model in which degeneration was induced via puncture, where
NC cells restored the loss of proteoglycans and maintained NP/AF
boundary.173 In the rtNC-treated IVDs, collagen type II was signifi-
cantly increased when compared with the degenerative control. As a
result, IVD height was increased compared with degenerative con-
trols.173
7.5 | Concluding remarks
NC cells are highly viable in the conditions related to the IVD and
have been shown to upregulate collagen type II and down-regulate
collagen type I, however limited studies have been able to preserve
their large vacuolated morphology and most suggest that they differ-
entiate into small NP-like cells when they are cultured in the harsher
degenerative IVD conditions.74,160,162,165 There are inconclusive
results for the ideal culture conditions of NC cells. The general con-
sensus is that due to their in vivo cluster form, 3D alginate bead cul-
ture is preferred; however, from all the studies extracted from the
literature review, no studies have investigated NC cells in biomate-
rials, other than alginate culture,43,161 to date. The lack of progression
with NC cells in studies could be explained by species-specific differ-
ence,¶¶¶ but also, and most likely, by variances in isolation protocols
and/or in culture conditions. As stated above, a valuable characteristic
of NC cells is their anti-angiogenic effects; the natural IVD conditions
and mechanical stimuli promote vascular growth, which if unchecked
may lead to a worsened state of IVD degeneration and contribute to
the symptoms of pain.165,174 The anti-angiogenic molecules produced
by NC cells have the potential to prevent such unfavorable conse-
quences. However, a key limitation of utilizing NCs is obtaining a suit-
able cell source as human IVDs do not retain NCs beyond
adolescence; xenografts would need to be deployed which also have
limitations. Furthermore, the difficulties seen in NC cell expansion/
culture, but the advantageous characteristics has led to alternative
approaches of developing hNC cells through iPSC60,70,71,175 (see Sec-
tion 13) or non-cell based therapy with the introduction of NC-condi-
tioned media and the potential use of NC matrix or growth factors
derived from NC cells.43,58
8 | CHONDROCYTES
Native characteristics, expansion capability and maintenance of phe-
notype in an intervertebral disc environment.
Chondrocytes harvested from different sources**** are able to
adapt their phenotype and differentiate into a spherical shape with
well-formed lacunae irrelevant of their in-situ culture system, for
example, nasal chondrocytes in in vitro 3D pellet culture,63 alginate
beads176 or in hydrogel,177 and auricular chondrocytes in vivo rabbit
IVD.178 Numerous reports evaluated the following cell surface pro-
teins as potential markers of chondrogenesis, namely CD29 in combi-
nation with CD49, CD146, and CD166,179 with Sox9 being the
strongest indicator of chondrocytic lineage.180,181
As chondrocytes also exhibit favorable properties for cartilage
repair, there are systematic reviews that have collated information on
the culture and expansion capability of chondrocytes; highlighting that
chondrogenic phenotype can be maintained using low glucose and
hypoxic conditions.182 Chondrocytes retain good expansion capability
with Fellows et al. (2017) reporting human chondrocytes retained
good viability after passage 9.††††182,183 Gay et al. (2019) conducted
an insightful study comparing articular and nasal chondrocytes, with
the chondrocytes harvested from the same animal model. The study
investigated how the cell types respond to different environments
that are associated with the IVD, such as altered oxygen and glucose
concentrations, within an in vitro pellet culture model. In this study
nasal chondrocytes were the cell type that displayed an increase in
DNA content in each condition, indicating that nasal chondrocytes
can survive, adapt, and proliferate favorably when directly compared
with articular chondrocytes.63,176 In vivo chondrocytes demonstrated
the potential for long-term survival of transplanted cells; transplanted
autologous auricular chondrocytes were shown to survive for at least
6 months in a rabbit model,178 and porcine articular cartilage remained
viable at 12 months post injection into a porcine model.184‡‡‡‡
Throughout the studies using chondrocytes for cell therapy for IVD
regeneration, the cells were shown to be tolerant to the IVD environ-
ment, most probably due to its similarities to the condition of cartilage
the chondrocytes are derived, and remain viable post-transplantation
in small animal models.63
§§§Conclusion; Table 1. NC cells ability to produce extracellular matrix is ranked 3, as these cells
produce proteoglycans at a higher fold than NP cells and extracellular matrix at the same
physiological GAG/DNA ratio.
¶¶¶Conclusion; Table 1. The potential adverse effects of using NC cells are ranked 1, as NC cells
used are xenogenous and could pose a rejection reaction.
****Conclusion; Table 1. Accessibility of chondrocyte cells is ranked 2, as these cells can be
harvested from multiple sources in the body, however they are invasive procedures and
could lead to injury at the site of cell source.
††††Conclusion; Table 1. Expansion capability of chondrocyte cells is ranked 2, as these cells can
be easily expanded in different in vitro culture systems, while still maintaining good viability
after several passages. However, they are limited by senescence.
‡‡‡‡Conclusion; Table 1. Survival capability of chondrocyte cells in IVD environment is ranked 3,
as it has be demonstrated that these cells can survival and proliferate in in vitro IVD
environment, and survive in the IVD of in vivo animal models.
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8.1 | Regenerative effect of chondrocytes
With the confirmation of sustained cell viability, the majority of studies
also investigated potential for restoration of the IVD through analyzing
matrix production. In normal conditions of 21% oxygen in a monolayer,
articular chondrocytes were able to up-regulate aggrecan, type I and
type II collagen mRNA, when compared with AF cells in the same condi-
tions.185 In conditions related to the IVD (hypoxic and low glucose), nasal
chondrocytes and articular chondrocytes were both capable of produc-
ing GAGs and collagen type I and type II.185 Furthermore, in the IVD
conditions nasal chondrocytes produced a ratio of low collagen to high
GAG content, whereas articular cells produced a less favorable high col-
lagen content.176 However, when acidic and inflammatory cytokines
were introduced to represent a degenerative IVD environment, neither
articular chondrocytes nor nasal chondrocytes deposited GAGs.63
In vivo transplantation of auricular and articular chondrocytes
within the degenerative NP resulted in the production of proteogly-
cans for up to 12 months in a porcine model184 and tissue formation
which resembled hyaline-like cartilage was apparent in a rabbit
model.178 Despite the chondrocytes' ability to express extracellular
matrix components, it was duly noted that the values were not in the
same range of magnitude as native tissue, with native healthy NP tis-
sue having a unique biochemical composition with a GAG to collagen
ratio of 27:1.37§§§§ Studies also assumed that the filling of the degen-
erate IVD with matrix produced from the chondrocytes, were deemed
“restored” and did not review how the composition, for example of
type I and type II collagens (which are usually understood to be an
unfavorable structure of scar tissue in knee joints), would fare in
restoring the biomechanical properties of the IVD. Therefore, it would
be logical to favor a cell source which can accumulate a similar, if not
equal, amount and type of extracellular matrix as a healthy NP.63
8.2 | Concluding remarks
Several different sources of chondrocytes have been utilized in stud-
ies where regenerating the IVD is proposed, including articular cho-
ndrocytes, nasal chondrocytes, endplate chondrocytes and auricular
chondrocytes. Signifying chondrocytes are readily available from mul-
tiple sources and could be autologous, although some sources are
more accessible than others. The ultimate issue with using cho-
ndrocytes as cell therapy, refers to the fact that they maintain their
chondrocyte phenotype in the IVD. This is not the characteristic we
want to observe in the NP, as chondrocytes produce cartilage and
extracellular matrix that is macroscopically more solid in comparison
to the gelatinous healthy NP,178 and does not contain the same com-
position as native NP.141 Despite these limitations, studies investigat-
ing chondrocytes for IVD regeneration, identify a cell type that is
reliable and stable, easy to expand in vitro and remains viable under
the harsh conditions of the IVD. Throughout these studies there was
no evidence of necrotic change, unfavorable bone growth,
transplanted cell migration, nor were there any active signs of tissue
vascularization.62,178,186¶¶¶¶ In fact, Acosta et al. (2011) demon-
strated that chondrocyte treated IVDs produced high levels of the
anti-angiogenic/neurogenic factor, chondromodulin-I, which lasted for
at least 12 months post injection.184 Chondrocytes are a viable option
for regeneration, if the correct IVD phenotype can be reproduced by
transplanted cells. Notably, there was a phase I clinical trial initiated
employing juvenile articular chondrocytes delivered in fibrin carrier
(“NuQu,” NCT01771471) which reported preliminary results in
15 patients in 2013,187 but the final outcome of the follow up phase II
study initiated for 44 patients has not yet been reported. Most proba-
bly, the availability of other more promising cell source alternatives
that are able to exhibit these NP like phenotypes, has resulted in cho-
ndrocytes being a less lucrative cell source for NP regeneration.
9 | ADULT STROMAL CELL SOURCES
Adult stromal cells are favorable for their self-renewal properties and
have a much greater interest than embryonic stem cells (ESCs) because
of several disadvantages of ESCs. hESC show notable tumorigenic prop-
erties, through an increase of telomerase activity, leading to high prolifer-
ation and potential formation of teratomas. Additionally, using
embryonic cells is surrounded by several ethical issues and there are lim-
ited use of embryonic cell lines, which have gained approval from
national legislations,188 therefore it is a less preferable option for future
IVD regeneration approaches.189 In contrast, adult stromal cells can be
isolated from various tissues including umbilical cord, bone marrow, and
adipose tissue and thus show greater accessibility for use.190
10 | BONE MARROW STROMAL CELLS
10.1 | Native characteristics, expansion capability,
and maintenance of phenotype
BMSC display similar fibroblastic morphologies, with an apparent mar-
ginally extending cytoplasm in monolayer culture, indicating plastic
adhesion ability.139,191-193 BMSC express cell surface markers, includ-
ing CD29, CD44, CD73, CD90, CD105, and CD166 and are negative
for typical markers of hematopoietic stem cells, CD34, leukocytes,
CD45, and endothelial cells such as CD14.177,193-195 BMSC can main-
tain cell markers in 90% of cells after passage 4/5177,196; however,
this cell type favors high-glucose condition (4.5 g/L) independent of
oxygen concentration.63 BMSC are easily manipulated, if exposed to
the appropriate stimuli in vitro, they can differentiate into osteogenic,
chondrogenic and adipogenic lineages.177,192,193,195*****
§§§§Conclusion; Table 1. Chondrocyte cell's ability to produce extracellular matrix is ranked 2, as
these cells were shown to be able to produce extracellular matrix in vitro and in vivo models,
however it did not resembled the phenotypic matrix observed in the NP.
¶¶¶¶Conclusion; Table 1. The potential adverse effects of using chondrocyte cells is ranked 2, as
using this cell source would not result in a regeneration of the native matrix production, thus
subjecting patients through treatments that results in no significant improvement.
*****Conclusion; Table 1. Expansion capability of BMSCs is ranked 3, as these cells can be easily
maintained after multiple passages and are easily manipulated into different cell lineages.
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10.2 | Cell survival in the intervertebral disc
environment
In vitro, altered hypoxic conditions resulted in an increase in cell viability
in rBMSC197,198 and reports of no change in metabolic activity
hBMSC.63,199,200 An observation that pro-inflammatory cytokine stimu-
lation does not change the hBMSC metabolic and cell activity.199 In con-
trast, when BMSC were cultured in IVD-like pH (6.8) or osmolarity of
485 mOsm, cell proliferation and expression of matrix proteins were
strongly decreased in rBMSC98 and in hBMSC.63 Suggesting that acidic
condition and high osmolarity were critical factors that reduced biosyn-
thesis and proliferation of BMSC in vitro. In a in vivo animal model of
IVD degeneration hBMSC have been reported to remain viable and sur-
vive in porcine IVDs for 6 months,196 rabbits for 3 months,201 rats for
6 weeks,202 and bovine for 3 weeks.195 Reports from in vitro and ex vivo
analysis show that when BMSC are subject to IVD-conditions they dif-
ferentiate toward NP-cell like phenotype,196,202 with elevated SOX-9
gene expression after 7 days203 and 14 days in vitro,63,191,204 and after
1 month202 and 3 to 6 months in vivo.196††††† Recently more efforts
have been made to differentiate BMSC into NP cells in vitro, utilizing the
IVD environment, such as using NP conditioned medium and hypoxia205
or co-cultured with NC-rich NP tissue.193
10.3 | Regenerative effect of bone marrow stem
cells
Human aspirated BMSC is frequently used to inject into models of
IVD degeneration in rabbits,201 rats,202 porcine,196 and
bovine,195,206,207 and are one of a few cell types that has been
established in human clinical trials.65,196,208-212 The introduction of
hBMSC in animal models resulted in increased collagen type II and
aggrecan expression,195,196,207 collagen type I196,207 was also
observed in small areas of NP, increased compared with degenerative
controls but less than healthy IVD. Interestingly, proteoglycans were
expressed throughout the NP region in hBMSC treated bovine IVDs,
even in areas void of cells.195 Analysis using transmission electron
microscopy displayed degenerative IVDs treated with hBMSCs pre-
served some lamellar organization, as well as a denser matrix in both
AF and NP, resembling the healthy bovine IVD control group.207
These results could be due to the observation that after the injection
of hBMSC studies have shown that the expression of SOX9 was
detected in the injected cells, indicating that when hBMSC are subject
to the IVD environment they tend to differentiate toward IVD-like
cells.‡‡‡‡‡196,200,202 However, BMSC have been shown to have
potentially adverse characteristics of migrating away from the injected
site. Henriksson et al.(2009) reported areas of tissue with limited
injected hBMSC cells and many studies have observed that BMSC
migrate away from the injection site; BMSC have been found distrib-
uted throughout the NP region,195 in the border zone between
NP and AF,196 and cells seeded onto the CEP migrated into the
NP.207,213§§§§§ Animal studies have demonstrated hBMSC capability
to differentiate into an NP-like phenotype, display matrix producing
properties and with no adverse bone mineralization being detected in
large animal models,196 therefore BMSC have transitioned to clinical
trials on human patients which has been reviewed recently.214
Patients used for BMSC clinical trials were selected based on
lower back pain diagnosed with IVD degeneration,65,209,211,212,215
lumbago,216 or their candidacy for spinal fusion or total dis-
cectomy.212 More specifically, the inclusion symptoms were
pain65,209,210,212,216; the presence of a posterior IVD bulge or small
protrusion209,210; or IVD height loss.65,212 Interestingly, two clinical
studies requested an intact annulus fibrosus ring capable of holding
cells.65,211 Only one study injected allogeneic hBMSC,65 while the rest
used patient derived autologous hBMSC. The allogeneic therapy
posed no safety concerns and was concluded to be a valid and a more
convenient alternative to autologous BMSC-treated patients.65 Qual-
ity control tests of karyotyping the BMSC were monitored and dis-
played that the injected BMSC characteristics remained stable over
time,211 with no adverse effects being reported in either allogeneic65
or autologous BMSC injection, also demonstrating safety.210 The
methods that were used to analyze the regenerative effects of BMSC
treatment differed between each clinical trial. In one study, 40% of
patients improved one modified Pfirrmann grade, with no radiographic
worsening.212 MRI analysis was used to assess the visual bulging of
the treated IVD. Reports of the reduction of the IVD posterior bulge
by an average of 23% after 6-month post-treatment,209 and another
study observed four out of five patients posterior protrusion reduced
by 20%, 43%, 40%, and 48%, with one patient displaying mild pro-
gression and a 25% increase in size of their posterior protrusion, after
4 to 6 year post-treatment.210 Water content was also analyzed
through MRI; BMSC treatment resulted in an observed increase in
water content in the IVD in patients after 12 months post-treat-
ment65,211 and visualized after 2-year post-treatment.216 Orozco et al.
(2011) reported that despite the increase in water content, IVD height
was not recovered through treatment.123 Throughout clinical trails
the assessment of pain and disability was the method of analyzing
regeneration. However, the studies had differing methods of scoring
and analyzing pain and disability, with some patients self-reported
overall quality of life improvements despite reports of continued IVD
degeneration.210 Four clinical trials utilized the Oswestry Disability
Index (ODI) to assess disability and visual analogue scale (VAS) to
evaluate pain; disability was reduced 3 months post-treatment, which
†††††Conclusion; Table 1. Survival capability of BMSCs in IVD environment is ranked 2, as
in vitro IVD conditions affected BMSCs biosynthesis and proliferation ability, however these
cells were able to survive in vivo animal models as they differentiated towards NP-like cells.
‡‡‡‡‡Conclusion; Table 1. BMSC's ability to produce extracellular matrix is ranked in IVD
environment is ranked 3, as in in vivo animal studies BMSCs that differentiate into NP-like
cells have shown their ability to produce NP native matrix, resulting in some disc
regeneration.
§§§§§Conclusion; Table 1. The potential adverse effects of using BMSCs is ranked 2, as in in vivo
animal studies BMSCs have shown to migrate away from the injected site, posing a risk of
bone formation in unwanted areas of the IVD. Additionally, BMSCs are used in clinical human
trails which have shown no overall significant change to LBP patients, as the use of BMSC
resulted in slowing down the degeneration of the disc and not regenerating the disc.
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was maintained till 12 months,65 12 months post-treatment,208 and a
slight reduction in disability was observed.65 Lumbar pain was acutely
reduced 3 months post-treatment, followed by minimal difference to
12 months,65 or patients that reported >25% reduction of posterior
bulge also reported lower pain score at 6 months post-treatment.209
Sciatic pain improved at 6 to 12 months post-treatment211 and 4-year
post-treatment lumbar and radicular pain improved.208 However, the
placebo effect has not been considered in clinical trials to date, which
should be investigated in randomized controlled trials.
10.4 | Concluding remarks
BMSC are easily sourced¶¶¶¶¶ and easy to differentiate in vitro,
once in an IVD environment BMSC commonly differentiate toward
NP-cell like phenotype, expressing NP markers CD24, KRT19, SOX-
9, aggrecan, collagen type II, and produce proteoglycans. These char-
acteristics transition into large animal models. However, in vivo
BMSC were not able to produce enough matrix to reverse the
degenerated IVD, as BMSC which were used to investigate regener-
ation of enzyme induced degeneration in an animal model with a
complete digested NP showed an inability to survive. While in a less
harsh degenerative IVD model, injected BMSC were unable to pro-
duce enough matrix comparable to a healthy IVD. One major limita-
tion was the ability of BMSC to migrate, as demonstrated when
BMSC appeared in the NP despite being seeded onto the CEP;
BMSC migrating from the CEP into the vertebrae may give rise to
BMSC differentiating into osteophytes, which has been reported of
BMSC leakage into adjacent vertebrae in a rabbit model.217 Despite
these potential adverse effects, clinical trials demonstrate the safety
and efficacy of autologous and allogeneic BMSC implanta-
tion.65,208,210-212 MRI displayed BMSC treatment improved moisture
content, IVD bulges were reduced, but no significant difference to
height of the IVD was observed. An acute decrease of pain and dis-
ability was reported post-treatment with BMSC, followed by modest
additional improvements. In one study 23% of patients elected to
proceed with surgery within 3 years post-treatment, as after 1 to
3 years ODI reduced to moderate disability.65,208 All in all, in most
cases BMSC treatment was effective at slowing down degeneration
but not regenerating the IVD.****** Further useful research may
involve NP regeneration in animal models with natural occurring IVD
degeneration, which includes all of the degenerative IVD chemical,
physical and mechanical microenvironment (as in vitro, BMSC were
observed to undergo apoptosis in IVD-like acidic conditions)53,197;
to evaluate and improve transplanted BMSC differentiation, regener-
ative effects and safety.218
11 | ADIPOSE DERIVED MESENCHYMAL
STROMAL CELLS
11.1 | Native characteristics, expansion capability,
and maintenance of phenotype
Isolated hADMSC grow as adherent monolayers with a spindle-shaped
and fibroblast-like morphology in vitro219-221 and exhibit high prolifera-
tion capability in appropriate culture conditions.220,222 When maintained
in standard culture conditions hADMSC expressed mesenchymal stem
cell markers CD73, CD90, and CD105, and lacked expression of hemato-
poietic cell markers CD14, CD34, and CD45, and the immunological cell
markers CD19 and HLA-DR.224,226 Similar to BMSC, these cells have the
ability to differentiate into osteogenic, chondrogenic and adipogenic line-
ages.220,222-224††††††
11.2 | Cell survival in intervertebral disc
environment
In a two-dimensional (2D) in vitro culture system, degenerate condi-
tions such as low acidity and high osmolarity impaired the viability
and proliferation of rADMSC124,225 and in hADMSC.226,227 Interest-
ingly, despite hyperosmolarity leading to lower cell viability and prolif-
eration, 400 mOsm/L resulted in the highest expression of SOX9,
aggrecan, and collagen II in comparison to 300 and 500 mOsm/L.225
The effect of inflammatory factors resulted in hADMSC producing
more pro-inflammatory cytokines and also enhanced osteogenesis.228
Low oxygen has also been shown to trigger hADMSC to produce
angiogenic and neurotrophic factors which would be detrimental for
IVD regeneration.199 In degenerated IVD models in vivo hADMSC
have been observed after 2 weeks,229 10 weeks,190 and 12 weeks
post-injection220 in small animal models and 16 weeks in Porcine ani-
mal model.222‡‡‡‡‡‡
11.3 | Regenerative effect of adipose derived
stromal cells
hADMSC have been studied in small animal models, using genetically
defective biglycan mice,220 rats and rabbit models subject to needle
puncture injury,190,230-232 in one large animal model222 and in a
human clinical trial.223 hADMSC diffused throughout the IVDs.220
Degenerative IVDs injected with hADMSC demonstrated an improve-
ment to GAG content with positive staining of collagen type II and
aggrecan at 2-week to 6-week post-injection in rat IVDs,230 at
¶¶¶¶¶Conclusion; Table 1. Accessibility of BMSCs is ranked 2, as these cells are easily sourced
from the bone marrow, however it is a painful and invasive procedure.
******Conclusion; Table 1. The potential adverse effects of using BMSCs is ranked 2, as in in vivo
animal studies BMSCs have shown to migrate away from the injected site, posing a risk of
bone formation in unwanted areas of the IVD. Additionally, BMSCs are used in clinical human
trails which have shown no overall significant change to LBP patients, as the use of BMSC
resulted in slowing down the degeneration of the disc and not regenerating the disc.
††††††Conclusion; Table 1. Expansion capability of ADMSCs is ranked 3, as these cells can be
easily maintained in different culture conditions and are easily manipulated into different cell
lineages.
‡‡‡‡‡‡Conclusion; Table 1. Survival capability of ADMSCs in IVD environment is ranked 1, as the
IVD conditions effected the proliferation and viability of ADMSCs. Additionally, the hypoxic
conditions resulted in these cells releasing adverse factors, which would further disc
degeneration.
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12-week post-injection in mice IVDs,220 and in rabbits at 18-week
post-injection.190 Structural organization of the degenerative IVDs
was improved at 4 weeks post-injury in rabbit models,232 at 12 weeks
post-injection in a mouse model,220 and 16 weeks in rat and rabbit
models.190,231 Despite the effect of ADMSC demonstrating some
regenerative properties throughout all these studies, only partial
regeneration of the IVD was demonstrated. Furthermore, the pres-
ence of small chondrocytes within the NP was observed in a rabbit
model190 and fibrous connective tissues were observed, which was
also present in degenerative controls.231 hADMSC displayed limited
proliferation capability in vivo, as 12 weeks post-injection hADMSC
were negative for the proliferation marker, Ki67,220 and human
nuclear antigen (HNA). HNA was expressed at 2 weeks yet had dis-
appeared by the 4-week to 6-week IHC analysis.230
There was a lack of larger animal studies that used hADMSC,
however analysis of the few studies demonstrated that the effects of
hADMSC did not change the level of aggrecan, or collagen type II in a
porcine model, but did result in a greater expression of Sox 9 in com-
parison to a degenerative IVD control at 21 days.222§§§§§§ This study
also analyzed the effect of human microfragmented adipose tissue
(hMFAT) seeded into the porcine model; MFAT contains a mixture of
cells including ADSCs and growth factors.223 MFAT resulted in a
homologous distribution of extracellular matrix and cells, additionally,
it showed the partial regeneration of the degenerate NP.223,233 Spe-
cifically, proteoglycans and collagen type II were easily detected, and
GAG content was comparable to normal non-degenerate controls.222
MFAT has the same composition as stromal vascular fraction (SVF) of
subcutaneous adipose tissue which has been used in human clinical
trials223; the difference between the SVF and MFAT is the enzymatic
and mechanical techniques used for isolation.222 In human clinical tri-
als, autologous SVF injection has improved pain, analysis with (VAS)
after 6 months post-treatment in 15 patients with degenerative IVD
disease223 and after 12 months post-treatment on chronic LBP
patients.221 In three patients who experienced improvement of pain
and disability, also simultaneously displayed increased water content
on MRI 12 months post-treatment.221 In human clinical trials there
was no reports of adverse events, including osteophyte formation or
incidence of infection.221,223¶¶¶¶¶¶
11.4 | Concluding remarks
ADSCs can be obtained by a simple surgical procedure which is rou-
tinely used in cosmetic surgery; one clinical trial reported patients
were discharged 4 hours from the start of harvesting autologous
ADMSCs until after cell transplantation. Harvesting of cells also
ascertains large quantities of cells, with additional ease in proliferation
in vitro under standard tissue culture condition.******* In vivo,
ADMSC results in partial regeneration of the IVD mainly through
extracellular matrix production, and there was no report of adverse
events. However, injection of ADMSC demonstrated evidence of low
cell survival in IVD-like environments in vitro which translated to poor
survival in vivo animal model studies. Moreover, ADMSC are very
angiogenic by nature223 and increased the expression of
proinflammatory molecules and promoted inflammation in NPC,222,228
which could contribute further to degeneration.
12 | UMBILICAL CORD STEM CELLS
12.1 | Native characteristics, expansion capability,
and maintenance of phenotype
The umbilical cord Wharton's jelly tissue contains stem cells similar to
adult MSC.234,235 In vitro hUCSC displays adherent growth, ability to
form cell colonies and exhibits fibroblast-like morphology.235-238 They
expressed typical MSC markers CD29, CD44, CD73, CD90, and CD105,
but were negative for CD14, CD34, and CD45235-238; with 98% to 99%
of cells positive for these MSC after five passages, with the exception of
CD105 which was positive in 75% of cells.236 hUCSC have self-renewing
capability, leading to high proliferation and have also demonstrated mul-
tidifferentiation capacity,235,239 differentiating into cells such as osteo-
genic, chondrogenic, and adipogenic cell lines,240-243 including muscle
cells,244 neural cells,245 and IVD cells.235†††††††
12.2 | Cell survival in the intervertebral disc
environment
In vitro cultured within a hypoxic environment irrelevant of culture
serum, hUCSC demonstrated NP differentiation, cells displayed a clus-
tering morphology, deposited GAGs, and expressed extracellular
matrix proteins.236 Exposure of NP cells taken from a degenerate IVD
to hUCSC conditioned media, has been shown to restore degenera-
tive NP cells to multipotent and self-renewing NP precursor cells that
expressed Tie 2+, OCT4, and Nanog.243 Furthermore, it has been
observed that mechanical IVD stimuli results in hUSC anti-apoptotic
effects; when co-cultured with hNP cells undergoing compressive
stress, the compression-induced apoptosis of NP cells was
suppressed.246 hUCSC were influenced to differentiate toward NP
cells with upregulation of ACAN, COL2A1, FOXF1, and KRT19 at
higher levels in vivo than in vitro (normal culture conditions; DMEM,
37C, 5% CO2.
237 hUCSC survived in rabbit IVD explants for
4 weeks,247 in vivo rabbit degenerative IVDs 8 weeks post-§§§§§§Conclusion; Table 1. ADMSC's ability to produce extracellular matrix is ranked 2, as in
in vivo small animal models resulted in improved matrix deposit, however in larger animal
models no difference in extracellular matrix production was observed.
¶¶¶¶¶¶Conclusion; Table 1. The potential adverse effects of using ADMSCs is ranked 2, as even
though there was no reports of ADMSC differentiation into unwanted bone formation,
transplanted ADMSC had low survival rate reducing the potential of regeneration and
increasing the risk of ADMSCs excreting detrimental factors, thus subjecting patients through
treatments that would result in no significant improvement.
*******Conclusion; Table 1. Accessibility of ADMSCs is ranked 3, as an abundance of cells are
collected in a simple surgical procedure.
†††††††Conclusion; Table 1. Expansion capability of hUCSCs is ranked 3, as these cells can be
easily maintained in different culture conditions and are easily manipulated into different cell
lineages
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injection,237 and canine degenerative IVDs 24 weeks post-injec-
tion.‡‡‡‡‡‡‡235
12.3 | Regenerative effect of umbilical cord stem
cells
hUCSC have been used in in vivo rabbit models,237,247,248 rat
models,238 and larger dog models.235 In degenerated animal IVD
models, treatment with hUCSC demonstrated partial preservation of
the NP region and increased structure in rabbit,237,249 rat,238 and
canine models.235 Aggrecan, type II collagen, and SOX-9 increased in
hUCSC injected groups when compared with the degenerate con-
trols,235,237,238,249 which also translated into an increase of matrix
gene expression.235 Interestingly collagen type I was downregulated
in the hUCSC injected group235 as well as inflammatory cytokines to
levels comparable to healthy controls.§§§§§§§238
MRI analysis of theNPdisplayed increased IVDheight andwater con-
tent in a rabbit degenerate model 8-weeks post-injection237 and in canine
models 8-weeks, 12-weeks, and 24-weeks post-injection.235 However,
there was no reported difference in MRI analysis after 12 weeks post-
injection,249 and MRI signals remained lower than in healthy control
IVDs.235 One major limitation observed in Beeravolu et al. (2018), was
human specific markers were observed in the AF of the injected IVD.
Either transplanted cells were not fully placed into the NP during injection
or like BMSC they are capable of migrating out of the NP
region.¶¶¶¶¶¶¶237 The mixedMRI analysis from in vivo testing were also
reiterated in a small clinical trial with hUCSC. Two patients that presented
with chronic low back pain were treated with hUCSC.239 After a 2-year
follow up post-treatment pain and function improved in both patients; the
first patient showed an immediate effect of pain relief (VAS), followed by
sustained effect up to 24 months, this was also observed in their disability
report (ODI), and translated into a greater MRI signal intensity compared
with pre-treatment, indicating higher water content in the NP. In the sec-
ond patient there was an acute regeneration with an improved pain (VAS)
and disability (ODI) score at 6months post-treatment, however the scores
progressively worsened following 12 and 24 months. Also correlating to
no notable increase ofMRI signal intensity.239
12.4 | Concluding remarks
hUCSC are harvested from the umbilical cord or placenta, which is
non-invasive, and readily available in blood banks; umbilical cord
displays low incidence of graft vs host disease and can be used
allogeneically.******** However, social, and ethical issues have been rec-
ognized surrounding the practice of blood collection, due to obtaining
consent and that blood banking is becoming more commercialized; a case
story of a private biotechnology company that enforced obstetricians to
halt blood collection to certain banks due to alleged patent infringement,
highlights these concern of commercializing.250 As with mesenchymal
stromal cells, hUCSC have the capability of high proliferation rates and dif-
ferentiating into multiple lineages, including NP cells, especially in the IVD
environment. In smaller animal models and larger animal models, hUCSC
demonstrated partial regeneration of NP degeneration; aggrecan and col-
lagen type II was deposited with a downregulation in collagen type I and
cytokines. However, there are some limitations with the migration ability
of hUCSC, which could lead to safety concerns. hUCSC have been tested
in human clinical trials with a small cohort, which showed initial improve-
ment to symptoms, although no regeneration was concluded. No adverse
events were found in the human patients,239 however, this study was lim-
ited by only using twopatients;more clinical studies are needed to identify
a reliable outcome for the use of hUCSC for regenerative purposes.
13 | INDUCED PLURIPOTENT STEM CELLS
13.1 | Native characteristics, expansion capability,
and maintenance of phenotype
iPSC can be generated from almost any type of somatic cell by intro-
ducing a combination of several reprogramming transcription factors,
such as Oct3/4, Sox2, KLf4, and c-Myc.251,252†††††††† Human iPSC
for use in NP regeneration has been generated from normal dermal
fibroblasts60,71 and NP cells.69 iPSC have a distinct morphology with a
prominent nucleolus and a high nucleus to cytoplasm ratio.
Pluripotency is characterized with the expression of OCT4, SOX2, c-
MYC, KLF4, and NANOG. iPSC have an unlimited proliferation capac-
ity and maintain normal karyotype in culture.69,71 iPSC can differenti-
ate into cells of all germ layers.253‡‡‡‡‡‡‡‡ However, rapid cell
growth and high plasticity allow iPSC to form teratomas in vivo,69
which are used to demonstrate iPSC pluripotency but would not be
favorable for treatment approaches.69,71 Thus, for applicability for
regeneration it is essential to differentiate the iPSC to the cell type of
choice for regeneration and purify by removing non-differentiated
cells or cells from other lineages prior to injection in vivo.
13.2 | Differentiation into notochordal-like cells
To generate induced NC-like cells (iNC-LC), iPSC can be subject to differ-
entiation via different methods; the most common method is firstly
‡‡‡‡‡‡‡Conclusion; Table 1. Survival capability of hUCSCs in IVD environment is ranked 2, as
these cells were able to survive in vitro IVD conditions and in vivo animal models as they
differentiate towards NP-like cells. However, they have not yet been investigated in a
degenerate environment.
§§§§§§§Conclusion; Table 1. hUCSCs ability to produce extracellular matrix is ranked 2, as in
in vivo animal models these cells were able to produce extracellular matrix native to the NP,
which resulted in partial regeneration.
¶¶¶¶¶¶¶Conclusion; Table 1. The potential adverse effects of using hUCSCs is ranked 1, as some
reports of transplanted cells migrating away from treatment site, and human clinical trials
have shown limited regeneration with the use of hUCSCs.
********Conclusion; Table 1. Accessibility of hUCSCs is ranked 3, as these cells are externally
sources and there is an abundance of hUCSCs in blood banks.
††††††††Conclusion; Table 1. Accessibility of iPSC is ranked 3, as these cells are generated from
almost any somatic cell and then stored in abundance in iPSC banks.
‡‡‡‡‡‡‡‡Conclusion; Table 1. Expansion capability of iPSC is ranked 3, as these cells can be
easily maintained, expanded in culture conditions, and are theoretically easily manipulated
into different cell lineages.
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differentiating iPSC toward primitive streak mesoderm, followed by plas-
mid transfection with NC transcription factors such as Brachyury, FOXA2
or NOTO to differentiate into an NC phenotype60,70,71,103; Xia et al.
(2019) differentiated hiPSC toward mesoblastic cells, followed by differ-
entiation intoNP-LC.254 Hu et al. (2020) used a lentivirus vector system to
transfectGDF5 todifferentiate hiPSC255; and hiPSCwere successfully dif-
ferentiated intoNC-like cells under the influence of native devitalized por-
cine NP matrix powder.256 iNC-LC have been shown to express typical
notochordalmarkers of brachyury, KRT8, KRT19, collagen type II, collagen
type I, and aggrecan.254,256 Furthermore, iNC-LC has been demonstrated
to survive in IVD retain the expression of KRT18, KRT19, brachyury,71 col-
lagen type II, and aggrecan175 phenotype of NC for up to 8 weeks post-
injection in a small178 and large degenerative animal model.§§§§§§§§72
13.3 | Regenerative effect of induced pluripotent
stem cells
Human iPSC co-cultured with pNP matrix powder to generate NP-like
tissue in vitro for 28 days, increased expression of Sox9, collagen type
II, and aggrecan.256 When iNC-LC were translated into animal models,
collagen type II, and aggrecan proteins were present following
8 weeks175 and 16 weeks post-injection in rat models,254 leading to
increased proteoglycan production and restored NP region.¶¶¶¶¶¶¶¶
In these small animal models, there was an observed IVD height
increase at 8 weeks175 and 24 weeks post-injection.254 Interestingly,
the injection of iNC-LC resulted in an increase in intradiscal pH,
12 weeks post-injection in a porcine model, indicating the cells were
able to influence their surroundings to produce a less degenerate
environment and potentially play a protective role.71
13.4 | Concluding remarks
iPSC are potentially an abundant cell source, as they can be obtained
through reprogramming somatic cells of the patient. iPSC also show
proliferation ability and the capacity to differentiate into a chosen cell
once appropriate differentiation protocols have been established.
Studies using iPSC have differentiated these stem cells into NC-like
cells but not differentiated to fully mature NP cells.69 Once iNC-LC
TABLE 1 Heat map showing the conclusion of cell type use to regenerate the degenerative nucleus pulposus of the intervertebral disc;
nucleus pulpous cells (NP), annulus fibrosis (AF) cells, notochordal (NC) cells, chondrocytes, bone marrow stem cells (BMSC), adipose-derived
stem cells (ADMSC), umbilical cord stem cells (UCSC), and induced pluripotent stem cells (iPSC)
Note: These cell type were ranked 1 to 3, 1 being inefficient, and 3 being efficient at accessibility of harvesting the cell type, expansion capability in vitro,
the ability of the cell type to survive in a intervertebral disc environment, the ability of the cell to produce extracellular matrix and the potential adverse
event that could potentially happen; deeming a safety issue.
§§§§§§§§Conclusion; Table 1. Survival capability of iPSC in IVD environment is ranked 2, as these
cells were able to survive in vitro IVD conditions and in vivo animal models as they
differentiate towards NC-like cells.
¶¶¶¶¶¶¶¶Conclusion; Table 1. iPSC's ability to produce extracellular matrix is ranked 3, as in
in vivo animal models these cells were able to produce extracellular matrix native to the NP,
which resulted in disc regeneration.
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are generated, these cells upregulate NP markers in vitro and increase
collagen type II and aggrecan expression in vitro and in vivo. Which, in
turn has shown a to halt IVD degeneration in animal models. How-
ever, iPSC ability to form teratomas in the IVD is a cause for concern,
however no teratoma formation was reported in these initial stud-
ies,71,175 which may be the result of stable phenotype of iNC-LC once
differentiated into a committed cell lineage.********* In conclusion,
the study of iPSC in animal models is novel and no iPSC are used clini-
cally at present, but preliminary results of seeding iNC-LC into degen-
erate IVDs in animal models shows promising results, with no safety
issues highlighted, or extensive studies, to date.
14 | DISCUSSION AND CONCLUSIONS
A key challenge of cell therapy is choosing an appropriate cell source
that can not only survive within the natural harsh environment of the
IVD, but also is safe to use and produces appropriate extracellular
matrix to restore biomechanical and biological function of the IVD.
One accommodating factor about the IVD is the avascular nature
(although this does change during degeneration); therefore, is consid-
ered immunoprivileged and should tolerate autologous or allogeneic
cells.257,258 The key characteristics of the ideal cell source are
assessed on their ability to proliferate in vitro, in order to obtain suffi-
cient number of cells for preparation as a therapeutic model, survive
in the IVD environment, regenerate the NP through the analysis of
extracellular matrix production and assure safety and long-term
effectiveness.
The first and most logical cells to regenerate the NP with would
be utilizing IVD cells themselves, NP, and AF cells. NP and AF cells
can survive in the NP and produce extracellular matrix in vivo.186
However, AF cells produce extracellular matrix that does not resemble
the native extracellular matrix of the NP. Furthermore, the harvesting
of NP cells involves a difficult invasive procedure, which results in a
limited cell number and inefficient expansion capacity limits the use of
NP and AF cells as a cell source potential greatly, although cadaveric
sources for NP cells are currently in clinical trials.118 In addition, NP
cells exposed to the degenerated IVD may result in NP cellular senes-
cence and contribute to an inability to produce proteoglycans30,259; as
this is a key factor in initial stages of IVD degeneration. NP cells dis-
play similar phenotypic characteristics to chondrocytes, sharing similar
morphology and some gene expression. Chondrocytes are readily
available from multiple sources, can be expanded in vitro and remain
viable in IVD condition. However, in vivo they retain their
chondrocytic phenotype and produce extracellular matrix that
involves a slightly different composition compared with NP extracellu-
lar matrix,141,178 thus affecting the biomechanical properties of the
IVD. Another cell type are IVD derived NC cells; these cells are of
notochordal origin and are pre-existing cells in the NP region of the
human IVD prior to adulthood. NC cells are capable of synthesizing a
proteoglycan-rich matrix and play a protective role in a catabolic
environment; however, they are hampered by difficulties in handling
them and acquisition. In particular the difficulties in maintaining
phenotype in monolayer culture in vitro,74,160,161 together with diffi-
culties in harvesting sufficient numbers due to difficulties with
amplification in vitro and their non-existence in mature human
IVDs.4,158,162
Alternatives are to utilize adult stromal cell differentiation into
NP-like cells. BMSC have good differentiation capacity and are easily
accessible. Animal models and clinical trials showed promising results
for partial regeneration of NP. However, the differentiation fluidity
resulted in adverse events such as osteophyte formation217 and
capacity of BMSC to migrate, applies a reason for concern with
unwanted bone formation if injected alone. While BMSC are the tar-
get of many clinical trials, results to date are limited to short term fol-
low up and thus longer-term results are awaited. Another source of
MSC are ADMSC, harvesting these cells is less invasive and can result
with larger cell quantities than BMSC extraction.229 In vitro they are
grown easily under standard conditions. Despite promising in vitro
results, and some extracellular matrix production observed in vivo,
ADMSC survival rates in IVD conditions in vitro and in vivo are low,
triggered by the hypoxic and inflammatory host environment.220,221
BMSC and ADMSC generally proliferate when exposed to inflamma-
tory conditions, especially where there is also oxidative stress; this
response is valuable in normal healing conditions and protects from
apoptosis.228,260 However, in the context of the degenerative IVD,
the increase in cells could result in depleting the already limited nutri-
ent supply of the IVD and thus may not provide regeneration. MSC
derived from perinatal tissues have less limitations than using BMSC
and ADMSC; hUCSC are more primitive and display a lower risk of
rejection,261 making these cells available for allogeneic transplants.
Human UCSC offers good differentiation capabilities and can be sub-
ject to differentiation into NP-like cells in IVD conditions. In smaller
and larger animal models, hUCSC demonstrated partial regeneration
of degenerate NP tissue, yet their observed migration ability is a limi-
tation, which may lead to safety concerns. In human clinical trials,
overall, there was an improvement in self-assessment of pain and dis-
ability and some reports of NP regeneration through MRI analysis.
There were no adverse events reported, displaying the safety of
hUCSCs in humans. However, this was a small cohort, and more stud-
ies are needed.
The final cells evaluated were iPSC, which could be used to gen-
erate NP-like cells. As there are no established precursors of NP cells,
differentiating iPSC into iNC-LC is proposed within the literature to
regenerate the IVD in the literature to date, however full characteriza-
tion of these cells and their function has not been completed. iPSC
can be generated from any somatic cell; therefore, they are highly
accessible and have an unlimited proliferation ability. As iPSC have
been used to differentiate into iNC-LC, they survive in IVD conditions
and have been shown to produce extracellular matrix in vivo, although
investigation of the true degenerate environment remains to be evalu-
ated. Furthermore, safety issues with these cells still need to be evalu-
ated, iPSC can form teratomas and the safety of viral transfection,
*********Conclusion; Table 1. The potential adverse effects of using iPSC is ranked 1, as there is
potential of iPSC to form teratomas, however there have been no reports in the few initial
in vivo studies with these cells.
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used to induce iPSC differentiation, on the cells' karyotype also needs
to be assessed. Based on the evaluation of all cell types (Table 1), iPSC
or BMPCs currently provide the highest overall potential for cellular
therapy to regenerate the NP, however further investigation is
required. If the safety of iPSC can be established, then utilizing iPSC
for cell therapy would provide improved accessibility compared with
NP, AF, NC, BMSC, and ADMSC; increased proliferation compared
with NP, AF, and NC cells; and at least in principle would be on par
with the ability of NC and NP cells to survive within the IVD environ-
ment and produce the desired extracellular matrix. The next question
would be which cell type would possess the greatest regenerative
potential in a degenerate IVD. Whereas injecting NP cells could cause
the injected cells to contribute to degeneration, limited knowledge is
known about the regenerative effects of NC cells.
This report concentrates on cell sources; however, there are other
important considerations that have extensive influence on cell behav-
ior, such as the addition of biomaterials and growth factors. Biomate-
rials are used as cell carriers, cell anchoring, a guide for extracellular
matrix synthesis and mechanical support; reviews have discussed cell-
biomaterial approaches of IVD tissue engineering.95,262,263 These
materials could be utilized to provide instructive cues and protection
to cells and thus must be considered in combination for future thera-
pies. Bowles and Setton (2017) have reviewed bioengineering
advances to treat IVD regeneration. Interestingly this biomaterial
review concludes too, that the regeneration of IVD must take into
consideration biological processes.263 Growth factors can also be
implemented to facilitate correct differentiation, or regenerative prop-
erties.194,231,255,264 For example, GDF5 gene transferred BMSC
upregulated aggrecan and SOX9 and KRT19 compared with non-
transfected cells, which was reported to lead to partial recovery of
GAGs in bovine degenerated IVD194; also pre-treated ADSCs with
SAG resulted in the improved IVD height, water content, extracellular
matrix content, and structure of degenerated IVDs in vivo.231 Few of
the studies cited in this review compared the treatment of cells only
and cells with biomaterials, there is evidence that when cells are used
in conjunction with a biomaterial, it can result in an enhanced regener-
ative effect on the IVD.103,238 Combining cells, biomaterial and
growth factors is the principle of a tissue engineering review by
Tendulkar et al. (2019), whose analysis focuses on the repair of NP
utilizing tissue engineering approach of injectable hydrogels, cells, and
growth factors.93
In summary, here we provide a rational discussion of potential cell
sources proposed for NP tissue regeneration, based on accessibility,
expansion capability in vitro, cell survival in the IVD environment,
regenerative effects of cells alone, and potential safety of the cells.
We propose that the use of iPSC-NC-LC as a cell source could have
the potential for regenerating the NP in degenerate IVDs and requires
further study to assess their regenerative ability and safety.
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